Nevro Stock Forecast, Price & News

+14.96 (+9.18 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.57 million shs
Average Volume446,632 shs
Market Capitalization$6.19 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Nevro logo

About Nevro

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.22 out of 5 stars

Medical Sector

956th out of 2,105 stocks

Surgical & Medical Instruments Industry

91st out of 174 stocks

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nevro (NYSE:NVRO) Frequently Asked Questions

Is Nevro a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nevro stock.
View analyst ratings for Nevro
or view top-rated stocks.

What stocks does MarketBeat like better than Nevro?

Wall Street analysts have given Nevro a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nevro wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Nevro

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its quarterly earnings data on Wednesday, May, 5th. The medical equipment provider reported ($0.85) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.86) by $0.01. The medical equipment provider earned $88.61 million during the quarter, compared to analyst estimates of $85.16 million. Nevro had a negative net margin of 24.16% and a negative trailing twelve-month return on equity of 23.26%.
View Nevro's earnings history

How has Nevro's stock been impacted by Coronavirus (COVID-19)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 62.0% and is now trading at $177.87.
View which stocks have been most impacted by COVID-19

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $104 million-$106 million, compared to the consensus revenue estimate of $101.14 million.

What price target have analysts set for NVRO?

11 brokers have issued twelve-month target prices for Nevro's stock. Their forecasts range from $160.00 to $225.00. On average, they expect Nevro's share price to reach $199.90 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price.
View analysts' price targets for Nevro
or view top-rated stocks among Wall Street analysts.

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. D. Keith Grossman, Chairman, CEO & Pres (Age 61, Pay $1.4M)
  • Mr. Roderick H. MacLeod, Chief Financial Officer (Age 54, Pay $546.9k)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 47, Pay $605.57k)
  • Mr. Andrew H. Galligan, Exec. Officer (Age 65, Pay $776.95k)
  • Ms. Niamh Louise Pellegrini, Chief Commercial Officer (Age 54, Pay $701.21k)
  • Mr. Patrick Schmitz, VP of Operations (Age 61)
  • Ms. Julie D. Dewey, VP of Investor Relations & Corp. Communications (Age 60)
  • Mr. Michael Collier Carter, VP of Global Sales (Age 49)
  • Mr. Jon R. Shear, VP of Corp. Devel.
  • Ms. Lori M. Ciano, Chief HR Officer (Age 58)

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (13.50%), BlackRock Inc. (11.09%), Fred Alger Management LLC (6.29%), Jackson Square Partners LLC (3.41%), Franklin Resources Inc. (2.93%) and D. E. Shaw & Co. Inc. (2.19%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, D. E. Shaw & Co. Inc., Tiger Eye Capital LLC, Northern Trust Corp, Integral Health Asset Management LLC, Jackson Square Partners LLC, Russell Investments Group Ltd., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have sold Nevro company stock in the last year include Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro
or view top insider-selling stocks.

Which institutional investors are buying Nevro stock?

NVRO stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Renaissance Technologies LLC, BlackRock Inc., Brown Advisory Inc., Great Point Partners LLC, Holocene Advisors LP, and Goldman Sachs Group Inc..
View insider buying and selling activity for Nevro
or or view top insider-buying stocks.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $177.87.

How much money does Nevro make?

Nevro has a market capitalization of $6.19 billion and generates $362.05 million in revenue each year. The medical equipment provider earns $-83,070,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Nevro have?

Nevro employs 843 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

Where are Nevro's headquarters?

Nevro is headquartered at 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.